製品名
Anti-BRCA1 (Ab-1) Mouse mAb (MS110), liquid, clone MS110, Calbiochem®
biological source
mouse
antibody form
purified antibody
antibody product type
primary antibodies
clone
MS110, monoclonal
form
liquid
contains
≤0.1% sodium azide as preservative
species reactivity
human
manufacturer/tradename
Calbiochem®
storage condition
do not freeze
dilution
(Frozen Sections
Immunoblotting (2 µg/mL)
Immunofluorescence
Immunoprecipitation
Paraffin Sections )
isotype
IgG1
shipped in
wet ice
storage temp.
2-8°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BRCA1(672)
Analysis Note
Positive Control
MCF7 cells
MCF7 cells
Application
Frozen Sections (see application reference)
Immunoblotting (2 µg/ml)
Immunofluorescence (see application reference)
Immunoprecipitation (see application reference)
Paraffin Sections (see application reference)
Immunoblotting (2 µg/ml)
Immunofluorescence (see application reference)
Immunoprecipitation (see application reference)
Paraffin Sections (see application reference)
Disclaimer
Toxicity: Standard Handling (A)
General description
Anti-BRCA1 (Ab-1), mouse monoclonal, clone MS110, recognizes the ~220 kDa BRCA1 protein in MCF-7 cells. It is validated for WB, IF, IP, and frozen and paraffin sections.
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells. Recognizes the ~220 kDa BRCA1 protein.
Recognizes the ~220 kDa BRCA1 protein in MCF-7 cells. Does not cross-react with blood group antigens or growth factor receptors such as EGFR. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
Immunogen
Epitope: within the N-terminal 304 amino acids of BRCA1
Human
recombinant human BRCA1
Legal Information
Sold under license of U.S. Patents 5,753,441 and 6,162,897.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Antibody should be titrated for optimal results in individual systems.
Scully, R., et al. 1996. Science272, 123.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R. 1995. Nat. Genet.11, 113.
Merajver, S.D., et al. 1995. Clin. Can. Res.1, 539.
Merajver, S.D., et al. 1995. Nat. Genet.9, 439.
Struewing, J.P., et al. 1995. Nat. Genet.11, 198.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Futreal, P.A., et al. 1994. Science266, 120.
Miki, Y., et al. 1994. Science266, 66.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R. 1995. Nat. Genet.11, 113.
Merajver, S.D., et al. 1995. Clin. Can. Res.1, 539.
Merajver, S.D., et al. 1995. Nat. Genet.9, 439.
Struewing, J.P., et al. 1995. Nat. Genet.11, 198.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Futreal, P.A., et al. 1994. Science266, 120.
Miki, Y., et al. 1994. Science266, 66.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.
Packaging
Please refer to vial label for lot-specific concentration.
Physical form
In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類
10 - Combustible liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Nerea Matamala et al.
Oncotarget, 7(15), 20068-20079 (2016-03-05)
Emerging evidence suggests that BRCA1 pathway contributes to the behavior of sporadic triple negative breast cancer (TNBC), but little is known about the mechanisms underlying this association. Considering the central role that microRNAs (miRNAs) play in gene expression regulation, the
Aruna Korlimarla et al.
PloS one, 11(4), e0153113-e0153113 (2016-04-15)
Apart from germ-line BRCA1-mutated breast cancers, a significant proportion of women with sporadic triple negative breast cancer (TNBC) sub-type are known to harbour varying levels of BRCA1-dysfuction. There is currently no established diagnostic method to identify these patients. The analysis
Geon Kim et al.
Oncology letters, 17(6), 5023-5029 (2019-06-13)
Breast cancer type 1 susceptibility protein (BRCA1) is a tumor suppressor gene that encodes a nuclear phosphoprotein, which is involved in homologous recombination to repair DNA double strand breaks and maintain genome stability. When BRCA1 is mutated or altered, DNA
Pierre Thouvenot et al.
Journal of cell science, 129(23), 4366-4378 (2016-11-02)
Understanding the effect of an ever-growing number of human variants detected by genome sequencing is a medical challenge. The yeast Saccharomyces cerevisiae model has held attention for its capacity to monitor the functional impact of missense mutations found in human
Young Eun Choi et al.
Oncotarget, 5(9), 2678-2687 (2014-05-07)
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit
グローバルトレードアイテム番号
| カタログ番号 | GTIN |
|---|---|
| OP92-100UGCN | 04055977209686 |
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)